References
- Awada A. [Development of new antineoplastic agents: 10 years of active clinical research marked by the evolution of treatment, from an empirical to a rational approach]. Bull Mem Acad R Med Belg 2001; 156: 338–47
- Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10: 6388–92S
- Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5025.
- Dhanda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):4534.
- Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505–12
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24
- Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516–24
- Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16–24
- Feldman DR, Kondagunta GV, Ronnen EA, Fischer P, Chang R, Baum M, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):5099
- Patel PH, Chadalavada RS, Chagnati RS, Motzer RJ. Targeting von Hippel–Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006; 12: 7215–20
- Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271–81
- Amato RJ, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):4530.
- Sosman JA, Flaherty K, Atkins MB, Puzanov I, McDermott DF, Vermeulen W, et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):3031.
- Azad NS, Posadas EM, Kwitkowski VE, Annunziata CM, Barrett T, Premkumar A, et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):3004.
- Ryan CW, Goldman BH, Lara PN, Jr, Beer TM, Drabkin HA, Crawford E. Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J Clin Oncol (Meeting Abstracts) 2006;24(18 Suppl):4525.
- Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27(2)187–93
- Fossa SD, Mickisch GH, De Mulder PH, Horenblas S, van Oosterom AT, van Poppel H, et al. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004; 101: 533–40
- Gao X, Reddy P, Dhanda R, Gondek K, Yeh YC, Stadler WM, Jonasch E. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2006; 24(18 Suppl)4604
- Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188–94